Gareth C. G. Davies, Neesha Dedi, Paul S. Jones, Lara Kevorkian, David McMillan, Cristina Ottone, Monika-Sarah E. D. Schulze, Anthony Scott-Tucker, Roohi Tewari, Shauna West, Michael Wright, Tania F. Rowley
{"title":"发现吉尼索坦单抗--一种用于治疗癌症的临床开发中的强效新型抗格雷姆林-1 抗体","authors":"Gareth C. G. Davies, Neesha Dedi, Paul S. Jones, Lara Kevorkian, David McMillan, Cristina Ottone, Monika-Sarah E. D. Schulze, Anthony Scott-Tucker, Roohi Tewari, Shauna West, Michael Wright, Tania F. Rowley","doi":"10.1080/19420862.2023.2289681","DOIUrl":null,"url":null,"abstract":"Gremlin-1, a high-affinity antagonist of bone morphogenetic proteins (BMP)-2, −4, and −7, is implicated in tumor initiation and progression. Increased gremlin-1 expression, and therefore suppressed...","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"37 1","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer\",\"authors\":\"Gareth C. G. Davies, Neesha Dedi, Paul S. Jones, Lara Kevorkian, David McMillan, Cristina Ottone, Monika-Sarah E. D. Schulze, Anthony Scott-Tucker, Roohi Tewari, Shauna West, Michael Wright, Tania F. Rowley\",\"doi\":\"10.1080/19420862.2023.2289681\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gremlin-1, a high-affinity antagonist of bone morphogenetic proteins (BMP)-2, −4, and −7, is implicated in tumor initiation and progression. Increased gremlin-1 expression, and therefore suppressed...\",\"PeriodicalId\":18206,\"journal\":{\"name\":\"mAbs\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2023-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"mAbs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/19420862.2023.2289681\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2023.2289681","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer
Gremlin-1, a high-affinity antagonist of bone morphogenetic proteins (BMP)-2, −4, and −7, is implicated in tumor initiation and progression. Increased gremlin-1 expression, and therefore suppressed...
期刊介绍:
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.